IMUC Up 40% On Positive Feedback From European Medical Agency

News: Phase 3 program given thumbs up for it's lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma


finance.yahoo.com/ne...atory-110000104.html